Navigation Links
Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil
Date:5/20/2009

Breakthrough Isolaz Pro to Launch into High Growth Brazilian Market for Aesthetic and Medical Procedures

PLEASANTON, Calif., May 20 /PRNewswire/ -- Aesthera announced today the receipt of ANVISA clearance to market their proprietary Isolaz Pro photopneumatic(TM) based platforms in Brazil. ANVISA (Agencia Nacional de Vigilancia Sanitaria) is a Brazilian national health surveillance and regulatory agency charged with clearing all applications to market medical devices in Brazil.

Aesthera also announced its partner in the region, Sao Paulo based LBT Lasers, a leading distributor of advanced aesthetic technology solutions for physician practices. Aesthera's Isolaz Pro and other soon to be launched technologies will be exclusively represented by LBT sales professionals in the Brazilian market.

"This is the most recent milestone in our aggressive build-out of Aesthera's international distribution channel. We look forward to partnering with LBT Lasers as we introduce the Isolaz Pro(TM) to Brazilian physicians," said Alon Maor, president and CEO of Aesthera Corp. Aesthera's Isolaz platform is the only FDA cleared device for the treatment of comedonal and pustular acne, in addition to being cleared for the skin rejuvenation and hair removal. "LBT Lasers has a longstanding reputation as a premier provider of innovative aesthetic technology. Their strong network coupled with large customer base of over 300 physician offices will accelerate the rapid adoption of Photopneumatic platforms to over 5000 dermatologists in the Brazilian marketplace," he adds.

"The Isolaz Pro platform will offer Brazilian physicians a much needed treatment solution for acne as well as Profusion - a breakthrough skin therapy to enhance skin treatment outcomes for acne, body tightening, skin rejuvenation and skin lightening," says Alexandre Ferraz, CEO, LBT Laser. "We are proud that Aesthera has selected LBT Lasers as their exclusive distributor in our region. The addition of Aesthera's products to our offering demonstrates our commitment to bringing only the most innovative and effective technologies to our Brazilian customers. The Brazilian market for aesthetics is strongly positioned for continued robust growth in the coming years," he adds.

Aesthera's Isolaz platform will be launched to the Brazilian market at key academic meetings starting with the Teraderm - Sociedade Brasileira de Dermatologia meeting (May 22 - 23, 2009), the Congresso Brasileiro de Medicina Estetica (June 3 - 6, 2009) and the upcoming Congresso Brasileiro de Cirurgia Dermatologica between June 10 - 14, 2009.

About Photopneumatic(TM) Technology

Photopneumatic Therapy, that powers the Isolaz(TM) and Isolaz Pro(TM) system, is a proprietary combination of pneumatic energy and broad band light. Photopneumatic devices are the only laser or light based devices cleared for the treatment of inflammatory acne, comedonal acne and pustular acne. They are also cleared for the treatment of mild to moderate inflammatory acne. Photopneumatic treatments have an immediate visible impact on acne 24 - 48 hour post first treatment and are painless. Facial treatments take approximately 10 minutes, require no anesthetics or numbing creams and provide additional cosmetic benefits such as smoother appearing skin. Additionally, Photopneumatic Therapy is also cleared for the treatment of benign vascular and pigmented lesions and hair removal.

About Aesthera Corporation

Aesthera (www.AESTHERA.com) develops, manufactures and markets light-based aesthetic treatment systems - the Isolaz(TM) and Isolaz Pro(TM) platforms - based on proprietary Photopneumatic(TM) technology.

    Contact:
    Sarvar Kothavala
    Aesthera Corp.
    415.760.0902
    SKothavala@Aesthera.com


'/>"/>
SOURCE Aesthera Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... Recent studies ... type. Many treatments for specific cancers, such as breast, prostate, or lung, target ... androgen deprivation therapy for advanced prostate cancer. , This therapy limits the ...
(Date:8/16/2017)... -- This year,s edition of the Inc. 5000 features a now-familiar name: BioPoint ... made the list for the third year in a row. Now in ... based on a set of quantitative metrics. In addition, BioPoint was also ... the Bay State . ... Inc. 5000 ...
(Date:8/15/2017)... CA (PRWEB) , ... August 15, 2017 , ... ... pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch of ... number of steps needed to gain kinetic binding data for a wide range ...
(Date:8/15/2017)... ... 15, 2017 , ... The Conference Forum and The Trout ... a series of upcoming panels and events. The partnership culminates with the 4th ... in New York City. , “With our experience in producing the Immuno-Oncology 360° NYC ...
Breaking Biology Technology:
(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
Breaking Biology News(10 mins):